Skip to main content
EJNMMI Research

Table 1 Patient characteristics for RHYTHM study

From: [18F]Fluoromisonidazole PET in rectal cancer

Median (IQR) or number of patients (%)

Group

RHYTHM B

Number

11

Age (IQR)

67 (19)

Male

9 (82)

Tumour stage (MRI)

 T2

2 (18)

 T3

9 (82)

 T4

-

Nodal stage (MRI)

 N0

4 (36)

 N1

6 (55)

 N2

1 (9)

Metastasis stage (CT)

 M0

11 (100)

Differentiation

 Well

1 (9)

 Moderate

6 (55)

 Poor

1 (9)

 Not specified

3 (27)

 Underwent TME

8 (73)

Response to CRTa

 Good

5 (45)

 Poor

6 (55)

  1. IQR interquartile range, CRT chemoradiotherapy, % percentage, TME total mesorectal excision, CT computed tomography, MRI Magnetic resonance imaging, AJCC American Joint Committee on Cancer, TRG ​tumour regression grade
  2. aGood response = AJCC TRG 0/1 with N0/1, or good clinical response; Poor response = AJCC TRG 2/3, N2 post-CRT or poor clinical response. One patient had delayed surgery due to initial good response, clinical outcome used
Back to article page